8th Australian Lung Cancer Conference 2020

8th Australian Lung Cancer Conference 2020:A Time of Hope in Lung Cancer19 - 21 February, 2020 Melbourne Convention and Exhibition Centre

In collaboration with: Endorsed by: Proudly sponsored by:

Platinum Gold Silver

Welcome delegates of the 8th Biennial Australian Lung Cancer Conference (ALCC).

In 2020, Lung Foundation Australia celebrates 30 years of service and support to Australians living with and impacted by lung disease and lung cancer. We acknowledge all those that have contributed to making the last 30 years a tremendous success, and most importantly we look forward with optimism to a brighter future, particularly for families whose lives have been forever changed by a lung cancer diagnosis.

As Chairperson of Lung Foundation Australia, I warmly welcome you to Melbourne, Australia and thank you for participating in the ALCC 2020. For the first time, the conference has joined with the Australasian Lung Cancer Trials Group Annual Scientific Meeting (ALTG-ASM) and will deliver a comprehensive three-day program to uniquely engage and unite lung cancer health professionals, consumer advocates and researchers from across Australia.

The ALCC program represents the shared strategic objectives of Lung Foundation Australia, the Australia & New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) and the ALTG. Together with ALTG, Lung Foundation Australia seeks to design and conduct clinical trials which contribute meaningfully to the evidence base for high quality lung cancer diagnosis, treatment and long-term monitoring. As outlined in our lung cancer report, ‘Making Lung Cancer A Fair Fight: A Blueprint for Reform’, our current key advocacy priorities include:

• Improving the quality of care for patients by increasing the number of lung cancer nurses.

• Implementing a targeted national lung cancer screening program.

• Increasing research funding for lung cancer commensurate to the burden of disease.

These initiatives have inspired the conference theme 2020: A Time of Hope in Lung Cancer. The scientific program seeks to highlight the social, economic and

mental health issues faced by Australians living with lung cancer. In 2020, the ALCC features multiple plenary sessions and offers delegates the opportunity to shape a unique learning experience through diverse concurrent sessions, ALTG member meetings, sponsor symposiums, and an exciting combination of evolutions in lung cancer treatment, technology, research and models of care. In another first, the program has been endorsed by the International Association for the Study of Lung Cancer (IASLC).

On behalf of Lung Foundation Australia, I would like to acknowledge and thank our event partners for their generous sponsorship; without such support ALCC could not take place. Thank you also to the Conference Convenors Prof Kwun Fong and A/Prof Thomas John, the Conference Organising Committee and Lung Foundation Australia staff for their efforts in shaping what will be an excellent event.

We hope you enjoy the ALCC 2020 and take the time to share with us your expertise and experience so we may continue to improve the lives of patients and families impacted by lung cancer and generate the translational evidence required for improvements in everyday clinical practice.

Yours sincerely,

Prof Christine Jenkins AM Chairperson Lung Foundation Australia

Welcome from Lung Foundation Australia

Australian Lung Cancer Conference 2020 Handbook2

ContentsWelcome from Lung Foundation Australia 2

Code of Conduct 4

Welcome from the Conference Co-Convenors 5

Meet the ALCC 2020 Local Organising Committee 6

International and Sponsored Speakers 7

Delegate and Speaker Information 11

Program

Wednesday 19 February 13

Thursday 20 February 14

Friday 21 February 16

Welcome from the Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) Chair 18

ANZ-LCNF Workshop Program 19

Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) Workshop Program 22

Abstracts: Poster Listing 24

Abstracts: Oral Presentations 26

How you can support us? 27


Code of Conduct The Local Organising Committee of ALCC 2020 welcomes all delegates to the conference, including consumer advocates. Whilst we are all united in the vision to improve outcomes for those affected by lung cancer, it is important to note that we come from varied backgrounds with unique experiences. To ensure that all delegates can make the most of the learning opportunities provided, in a safe and respectful environment, we ask you to please read and observe the following throughout your conference experience.

• We support and encourage consumer advocates to participate in the conference program and their right to be heard and respected. Consumer advocates are permitted to ask questions in allocated question times and enter the exhibition area when wearing their conference lanyard.

• A dedicated Consumer Advocates Lounge will be open (Room 101) throughout the course of the conference. This area will be a quite space where refreshments will be available for consumer delegates and approved users only.

• The program is designed to increase understanding of the advances in lung cancer research, treatment and care. When considering your questions to speakers, please note some of the tests and/or treatments presented may not yet be available in Australia.

• Health professionals, researchers and pharmaceutical representatives are unable to provide consumer advocates with individualised advice on medical conditions or any aspect of treatment.

• We are committed to providing a conference environment in accordance with the Medicines Australia Code of Conduct and specifically ask that all delegates and exhibitors are aware that individual promotion of products to the general public is in breach of the Code.

Acknowledgement of CountryLung Foundation Australia respectfully acknowledges the Boon Wurrung and Woiwurrung (Wurundjeri) peoples of the Kulin Nation as the Traditional Owners of the land upon which the Australian Lung Cancer Conference 2020 is being held. The Melbourne Convention and Exhibition Centre is built on their ancestral lands and we pay our respects to them, and to their elders, past, present and emerging.


Welcome from the Conference Co-ConvenorsOn behalf of Lung Foundation Australia, it gives us enormous pleasure to welcome you to Melbourne and to thank you for participating in the 8th Biennual Australian Lung Cancer Conference (ALCC).

For the first time the ALCC and the Australasian Lung Cancer Trials Group Annual Scientific Meeting (ALTG-ASM) have joined forces to deliver a comprehensive program which will no doubt uniquely engage and unite lung cancer health professionals, consumers and researchers. We are delighted that the event has been endorsed by the International Association for the Study of Lung Cancer (IASLC).

The ALCC 2020 conference program represents the strategic objectives of both Lung Foundation Australia and ALTG. Lung Foundation Australia’s current key advocacy efforts include improving access to treatment and lung cancer nurses, implementing a national lung cancer screening program and funding of lung cancer research commensurate with the burden of disease. These initiatives, as outlined in ‘Making Lung Cancer A Fair Fight: A Blueprint for Reform’, inspire the theme of ALCC 2020. The report addresses the social, economic and mental health issues of Australians living with lung cancer. Together, with initiatives by ALTG to design and conduct trials which contribute to evidence for high quality diagnosis, treatment and monitoring of lung cancer, we strive to effect change in the health and wellbeing outcomes of lung cancer patients.

The ALCC 2020 program is an exciting combination of evolutions in treatment, technology, research and supportive care. The conference will feature oral and poster sessions, sponsored symposiums and ALTG member meetings. The pre-conference events include Australia New Zealand Lung Cancer

Forum (ANZ-LCNF) Nursing and Allied Health Workshop and the Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) workshop. We are delighted to welcome delegates from across Australia, New Zealand and the international representatives, who collectively provide valuable insight into local and international advances in lung cancer. We thank you for attending and for the significant support provided by sponsors and exhibitors. Please take the time to visit our exhibitors during the designated breaks. We hope you enjoy the meeting and share with us your expertise and experience so we can continue to improve outcomes for lung cancer and generate the evidence required for improvements in clinical practice.

Yours sincerely,

Professor Kwun Fong

Co-Chair, Local Organising Committee

Associate Professor Thomas John

Co-Chair, Local Organising Committee


Meet the Local Organising CommitteeProfessor Kwun Fong Thoracic and Sleep Physician at The Prince Charles Hospital and Professor with the University of Queensland School of Medicine.

Associate Professor Thomas John Medical Oncologist at the Peter MacCallum Hospital in Melbourne.

Professor Fraser Brims Consultant Respiratory Physician and Head of Department Sir Charles Gairdner Hospital.

Dr Vanessa Brunelli Research Fellow at Queensland University of Technology and Nurse Researcher at Princess Alexandra Hospital.

Mary Duffy, RGN/RSCN, RSM Graduate Diploma of Advanced Nursing in Oncology and Palliative care. Master of Philosophy by Nursing Research.

Dr Lara Edbrooke Grade 4 Allied Health Researcher and Physiotherapist at Peter MacCallum Hospital.

Dr Kerry Hancock General Practitioner and Principal, Chandlers Hill Surgery, Happy Valley SA.

Associate Professor Gerry Hanna Director of Radiation Oncology at the Peter MacCallum Cancer Centre, Melbourne.

Associate Professor Marie-Liesse Asselin-Labat Joint-Head of the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research in Melbourne.

Dr Ashanya Malalasekera Medical Oncologist and Senior Lecturer at the University of Sydney.

Associate Professor Rob Stirling Respiratory Specialist at The Alfred Hospital, Melbourne and Chairman of the Lung Cancer Multidisciplinary Team.

Dr Jaclyn Yoong Palliative Care Physician and Medical Oncologist at Northern Health and Monash Health.

Dr Lisa Briggs- Consumer Advocate and 5-year Stage IV lung

cancer survivor

- Passionate about improving the visibility of lung cancer in Australia

- Wife and Mum

- Victorian Finalist - 2020 Australian of the Year ‘Local Hero’ category

- Member, Lung Cancer Patient Advisory Committee, Lung Foundation Australia

Tom Wood- Consumer Advocate

- Passionate about equity, technology and news

- Son, Brother and Carer

- Member, Lung Cancer Patient Advisory Committee, Lung Foundation Australia


International and Sponsored Speakers

Professor Michael Boyer AM Professor Michael Boyer is a Medical Oncologist and the Chief Clinical Officer at Chris O’Brien Lifehouse. He is a Conjoint Professor of Medical Oncology (Thoracic Oncology) at the University of Sydney and Director of the Sydney Catalyst Translational Cancer Research Centre.

Professor Boyer has over 25 years of experience in the management of thoracic

Dr Federico Cappuzzo MD

Dr Federico Cappuzzo has been the Director of Medical Oncology at AUSL della Romagna-Ravenna since April 2016 and in January 2017 he became the Director on Hematology and Oncology Department.

Dr Cappuzzo is a member of the Italian Association in Medical Oncology, European Society for Medical Oncology, American Society Clinical Oncology and International

Dr Marina Chiara Garassino

Dr Marina Chiara Garassino is the Chief of the Thoracic Oncology Unit at the prestigious Istituto Nazionale dei Tumori cancer institute in Milan, Italy.

She leads the strategy for clinical and translational research in advanced and locally advanced non-small cell lung cancer, small-cell lung cancer, mesothelioma and thymic malignancies.

malignancies and head and neck cancers. His main research interest is in clinical trials of new agents in the management of lung cancer, mesothelioma and head and neck cancers. He is the author of over 170 publications, has given numerous national and international presentations, both invited and selected from abstract submission, and is actively involved in the lung cancer community.

Association for the Study of Lung Cancer (IASLC) and since 2006 as a Member of the editorial board of Lung Cancer.

In January of 2016, he became the Chairman of the Educational Committee of IASLC. In 2006, 2009 and 2012 he received research grants from the Italian Association for Cancer Research on targeted therapies in lung cancer and is the author of more than 200 papers in peer-review journals, mainly in translational research in lung cancer.

Dr Garassino's main research interests include; the development of new drugs, therapeutic strategies and biomarkers. Dr Garassino has contributed to over 120 peer-reviewed publications, including credits as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology. Dr Garassino has delivered many presentations at international conferences including American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), European CanCer Organisation, European Society of Medical Oncology (ESMO), World Conference on Lung Cancer (WCLC).

Dr Garassino is currently serving as ESMO Council Chair of the National Societies Committee and serves on several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology Committee, Lung Cancer faculty, Membership Committee).

Dr Garassino is working on both ESMO, WCLC and ASCO annual congress Lung Cancer Track (2019). Dr Garassino is the founder and president of Women for Oncology Italy.


Professor Nir Peled MD PhD

Professor Nir Peled is Head of the Oncology Division at the Legacy Heritage Oncology Center and Dr Larry Norton Institute at Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel. He is board certified in internal medicine, pulmonology, and medical oncology.

An expert in thoracic oncology, Professor Peled is a Board Member at the

Professor Angela Mary Tod

Professor of Older People and Care, Division of Nursing and Midwifery at the University of Sheffield.

For the last 20 years Professor Tod has worked in research with a particular focus in lung cancer and mesothelioma patient experience studies. Professor Todd established and chaired the Lung Cancer Nursing UK Research Interest Group with a

International Association for the Study of Lung Cancer (IASLC) and the past Chair of the Thoracic Cancer Assembly of the European Thoracic Society and the past Chair of the Screening Committee of the International Association of Lung Cancer.

Professor Peled’s research focuses on the wide translational and clinical perspectives of lung cancer, including personalised targeted therapy, immunotherapy, cancer evolution, biomarker development, and early detection of this disease. He has published nearly 200 peer-reviewed articles, including guidelines on the early diagnosis of lung cancer, biomarker development, and treatment of advanced disease. Professor Peled is on the editorial board of numerous journals, including the Journal of Thoracic Oncology and other lung-cancer related publications. In October 2019 he became a board member of the IASLC and member of its financial committee.

portfolio of research projects in collaboration with Mesothelioma UK.

Professor Tod is also a Joint Principle Investigator on a National Strategic Research Alliance between the University of Sheffield and the Royal College of Nursing in the UK. This alliance incorporates a programme of work on new and emerging nursing roles including advanced and specialist nursing.

A/Prof Nick Pavlakis

A/Prof Nick Pavlakis is a senior staff specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Associate Professor in the Faculty of Medicine University of Sydney. He is currently Clinical Services and Trials Director of the Northern Cancer Institute at St Leonards, President of the Australasian Lung Cancer Trials Group (ALTG) and President of the Clinical Oncologic Society of Australia

(COSA). His background includes a PhD in anti-angiogenic cancer drug development and a Masters of Clinical Epidemiology, University of Sydney. He has extensive experience in clinical research as clinical lead or site Primary Investigator in national and international clinical trials in lung cancer, mesothelioma and gastrointestinal cancers, as well as translating evidence into practice with lung cancer systematic reviews and guideline development.


A/Prof Trishe Leong

A/Prof Trishe Leong is the Medical Director of Pathology and Director of Anatomical Pathology at Austin Health, Melbourne, where she has been involved in the supervision and reporting of diagnostic molecular testing for solid tumours since 2015. She received her undergraduate medical degree from the University of Adelaide and trained in Anatomical Pathology in Melbourne, being admitted to Fellowship in

2006. Following this she worked at Monash Medical Centre and the Victorian Cytology Service, where she was Deputy Managing Pathologist, before joining Austin Health in 2010. She previously served from 2015-2018 as the Honorary Treasurer of the Australasian Division of the International Academy of Pathologists, followed by a term as Divisional Vice President, and is the current Secretary/Treasurer of the Royal College of Pathologists Australasia.


See you at the ALCC 2020 Dinner!Thursday 20 February 2020

Join us for dinner and live entertainment as we announce and celebrate the recipients of the Lung Foundation Australia Lung Cancer Research Awards for 2020.

Welcome drinks from 7:00pm for 7:30pm commencement.

Places are limited and registration is required to attend. Visit events.ozaccom.com.au to register.

Please take time to visit the exhibition and engage with our event sponsors. Download the myINTERACT app to collect points and win prizes!

Trade Displays• Becton Dickinson

• Roche Foundation Medicine

• Takeda

• Maurice Blackburn Lawyers

• Healthinc

• Cancer Council Victoria

• Victorian Tumour Summits

Thank you to our generous event sponsors

Platinum

Gold

Silver


Delegate and Speaker Information Registration desk hours Registration desk is located on Level 1, open from:

Wednesday 19 February: 7:30am – 4:30pm

Thursday 20 February: 6:30am – 4:30pm

Friday 21 February: 6:30am – 2:00pm

Speaker Preparation RoomThe speaker preparation room is located on Level 1, Room 107 and is open:

Thursday 20 February: 6:30am – 5:00pm

Friday 21 February: 6:30am – 4:00pm

Social MediaThe official conference social media channels are:

Twitter: @Lungfoundation

Facebook: @Lungfoundation

Instagram: @Lungfoundation

LinkedIn: Lung Foundation Australia

Hashtag #ALCC2020 and tag us social media.

Event CoordinatorLisa Cunningham, Senior Event Manager, Medical Meetings

Contact number: 0435 569 096

Email: [email protected]

Should you require assistance or have questions throughout the event please speak with a member of the Medical Meetings team.

Poster DisplayPosters will be on display throughout the duration of ALCC 2020 in Room 104 and oral presentations will take place during morning tea and lunch breaks. Please take time to view the posters over a complimentary coffee, kindly provided by MSD.

MCEC Free Wifi Free WIFI is available at the conference. To connect to WIFI, select the MCEC Free WIFI Network, no password is required.

Conference CateringAll conference catering will be served in the exhibition area. Delegates who have advised special dietary requirements will have access to a separate buffet which will be supervised by an events staff member for your convenience. If you are attending a catered sponsor symposium, please arrive early to collect your meal.

Evaluation Your opinion is important to us! A post-event survey will be available from morning tea on Friday 21 February via the conference app. Please take the time to complete the evaluation to help us improve future ALCC events. After completing the evaluation, you will have access to the speaker presentations.

Consumer Advocates Lounge The dedicated consumer advocates lounge is located in Room 101 and is accessible throughout the conference by consumer advocate delegates only.

Conference App Download the myINTERACT app to:- View the ALCC program, abstracts and exhibitor

details- Complete session evaluations- Engage with exhibitors and win great prizes- Snap and upload the best conference photo to win

movie passes.

myINTERACT is available on iPhone, Android, Tablet and Desktop.


Please review the Product Information for TECENTRIQ (www.roche-australia.com/productinfo/tecentriq),AVASTIN (www.roche-australia.com/productinfo/avastin), ALECENSA (www.roche-australia.com/ productinfo/alecensa) and TARCEVA (www.roche-australia.com/productinfo/tarceva) before prescribing, available on request from Roche Products Pty Limited. Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney

NSW 2000. Medical Information: 1800 233 950. ®Registered Trademark EMVTEC462 EC-AU-9128 PreparedJan20

Lung cancer patients in mindTogether. Today and Tomorrow

People, products and services working together to support

you and your patients with lung cancer

atezolizumab bevacizumab alectinib 150 mg capsules erlotinib

Please review the Product Information for TECENTRIQ (www.roche-australia.com/productinfo/tecentriq),AVASTIN (www.roche-australia.com/productinfo/avastin), ALECENSA (www.roche-australia.com/ productinfo/alecensa) and TARCEVA (www.roche-australia.com/productinfo/tarceva) before prescribing, available on request from Roche Products Pty Limited. Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney

NSW 2000. Medical Information: 1800 233 950. ®Registered Trademark EMVTEC462 EC-AU-9128 PreparedJan20

Lung cancer patients in mindTogether. Today and Tomorrow

People, products and services working together to support

you and your patients with lung cancer

atezolizumab bevacizumab alectinib 150 mg capsules erlotinib

Wednesday 19 FebruaryTime Session Speaker Room

8:00am - 5:00pm Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) Nursing and Allied Health Workshop

For full workshop details please see page 19

9:00am - 4:00pm Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) Workshop

For full workshop details please see page 22

9:30am - 5:00pm Australasian Lung Cancer Trials Group (ALTG) Clinical Development Workshop and Open SAC Meeting

Room 101/102

10:00am - 4:00pm Lung Cancer Community Forum Room 103


NOW PBS LISTEDFirst-line treatment of Stage IV mNSCLC,

no EGFR/ALK/ROS1 genomic tumour aberrations; WHO PS 0-1; further eligibility

criteria apply1

SELECTED SAFETY INFORMATION• Immune-mediated adverse reactions, including severe and fatal cases have occurred in patients receiving KEYTRUDA. These included: pneumonitis, colitis, hepatitis, nephritis (nephritis appears to be

more common when KEYTRUDA is used in combination with pemetrexed and platinum chemotherapy than when KEYTRUDA monotherapy); endocrinopathies including adrenal insufficiency, uveitis, myositis, Guillain-Barre syndrome, myasthenic syndrome/myasthenia gravis, sarcoidosis, encephalitis, myocarditis, pericarditis, and pericardial effusion, peripheral neuropathy, severe skin reactions, solid organ transplant rejection and severe infusion reactions (hypersensitivity, anaphylaxis).2

• Although a direct comparison has not been undertaken, the frequency of adverse reactions for KEYTRUDA combination therapy is observed to be higher than for KEYTRUDA monotherapy or chemotherapy alone, reflecting the contributions of each of these components.2

• In a pooled population (n=2799) of previously untreated and treated patients with melanoma and mNSCLC. Treatment-related serious adverse events (SAEs) reported up to 90 days after the last dose occurred in 10% of patients receiving KEYTRUDA. Of these treatment-related SAEs, the most common were: pneumonitis, colitis, diarrhoea, and pyrexia. The most common treatment-related adverse reactions (reported in >10% of patients ) were: fatigue, pruritus, rash, diarrhoea, and nausea.2

In PD-L1 Expressors and Non-Expressors2

HELPING TO REDEFINE SURVIVAL EXPECTATIONS FOR PATIENTS WITH mNSCLC*†2

*Non-Squamous: without EGFR/ALK genomic tumour aberrations, KEYTRUDA + pemetrexed + platinum chemotherapy vs pemetrexed and platinum chemotherapy (HR=0.49; 95% CI, 0.38-0.64; P<0.001)2†Squamous: KEYTRUDA + carboplatin + paclitaxel/nab-paclitaxel vs carboplatin + paclitaxel/nab-paclitaxel (HR 0.64; 95% CI: 0.49–0.85; p<0.001)2

Before prescribing, please review the Product Information. Product Information available at www.msdinfo.com.au/keytrudapi or on request from Merck Sharp & Dohme (Australia) Pty Limited.

References: 1. Australian Government, Department of Health. The Pharmaceutical Benefits Scheme. Available at: www.pbs.gov.au/pbs. Accessed on: 15 JANUARY 2020 2. KEYTRUDA Australian Approved Product Information www.msdinfo.com.au/keytrudapi.Copyright© 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., inc., Kenilworth, NJ, USA. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road, Macquarie Park NSW 2113. AU-KEY-00402. First issued January 2020. essence MSD9535

PBS Information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.

Thursday 20 FebruaryTime Session Speaker Room

7:00am - 8:00am Australasian Lung Cancer Trials Group MAC Meeting (ALTG members only)

Room 102

8:00am - 9:00am Opening ceremony Prof Kwun Fong Prof Tom John

Room 105/106

9:00am - 10:00am Keynote presentations:

Future directions for research in Lung Cancer

Air quality and lung health

Dr Marina Garassino Prof Bin Jalaludin

Room 105/106

10:00am - 10:30am Morning tea (exhibition area) Poster presentations (Room 104)

10:00am - 12:30pm Palliative care symposium Dr Jaclyn Yoong Dr Michael Chapman Dr Eswaran Waran Prof David Currow Prof Jane Phillips

Room 103

10:00am - 12:30pm Plenary: Quality in Diagnostics and Care: ‘Leaps & bounds’ in lung cancer in 2020

A/Prof Marie-Liesse Labat Dr Stephen Fox Dr Federico Cappuzzo A/Prof Gerry Hanna A/Prof Gavin Wright Dr Lara Edbrooke Ms Mary Duffy

Room 105/106

11:30am - 12:30pm Pfizer Symposium: Lung pathology in the era of targeted therapies: ROS1 testing in patients with advanced non-small cell lung cancer

A/Prof Nick Pavlakis A/Prof Trishe Leong

Room 109

12:30pm - 1:30pm Lunch (exhibition area) Poster presentations (Room 104)

12:30pm - 2:00pm Roche Symposium: Non-squamousNSCLC: Selecting the right treatment regimen for each patient

Dr Federico Cuppuzzo Room 110

1:30pm - 3:00pm Symposium: Basic ScienceNovel insights into the biology of thoracic cancers

Dr Melvin Chin Dr Clare Weeden Dr Jason Cain Dr Mark Adams Dr Sarah Best Dr Marian Burr

Room 102


Thursday program continued

Time Session Speaker Room

1:30pm - 3:30pm Plenary: Hope & Equity Reinventing clinical trials

Prof Ben SolomonA/Prof Nick Pavlakis A/Prof Rob Stirling A/Prof Gavin WrightA/Prof Tom JohnRenae GrundyLisa BriggsTom WoodMelanie LaneLillian Leigh

Room 105/106

1:30pm - 3:30pm Living with Thoracic Cancer and Beyond: Exercise in lung cancer

Prof Linda Denehy Dr Vin Calvaheri Ms Jane Turner Prof Rob Newton Dr Jin-Soo Kim Ms Nasreen Kadaan

Room 109

1:30pm - 3:30pm Oral abstract presentations: Screening and early detection

Room 103

3:30pm - 4:00pm Afternoon Tea

4:00pm - 5:00pm Oral abstract presentations: Epidemiology

Room 103

4:00pm - 5:30pm Plenary: Living with Thoracic Cancer and Beyond: Holistic long-term care

Ms Olivia Wong Dr Catherine Holiday A/Prof Joel Rhee Dr Maria Ftanou Dr Jaclyn Yoong Ms Jacqueline Lesage Dr Melissa Yang

Room 105/106

4:00pm - 6:00pm ALTG clinical trial concepts Room 102

6:00pm - 7:30pm MSD Symposium: Redefining survival expectations for lung cancer patients

Prof Nir Peled Room 103

7:00pm - 11:00pm ALCC 2020 Conference dinner & Lung Foundation Australia lung cancer awards

Room 109/110


Friday 21 FebruaryTime Session Speaker Room

7:00am - 9:00am ALTG Strategic planning meeting (ALTG members only)

Room 102

7:30am - 9:00am BMS: What is the future of immunotherapy in NSCLC?

Prof Michael Boyer Room 101

9:00am - 10:00am Keynote presentation:

Working Together: The power of a multi-disciplinary approach in lung cancer treatment & care

E-cigarettes: Good intentions gone awry? The harmful consequences

Prof Angela Tod Prof Martin Phillips

Room 105/106

10:00am - 10:30am Morning tea (exhibition area) Poster presentations (Room 104)

10:30am - 12:30pm Oral abstract presentations: Medical oncology

Room 102

10:30am - 12:30pm Oral abstract presentations: Are we delivering best practice treatment?

Room 103

10:30am - 12:30pm Plenary: Quality in Diagnostics and Care: Lung cancer screening in Australia

Dr Vivienne Milch (Cancer Australia) Dr Henry Marshall A/Prof Paul Mitchell Dr Brendan Adler Dr Niranjan Karanth Prof Nir Peled

Room 105/106

10:30am - 12:30pm Symposium: Borderline inoperable disease

Mr Julian Gooi Dr Susan Harden A/Prof Siven Seevanayagam Dr Fiona Hegi-Johnson

Room 109

12:30pm - 1:30pm Lunch (exhibition area) Poster presentations (Room 104)


Time Session Speaker Room

12:30pm - 2:00pm AstraZeneca Symposium: Putting evidence into practice in locally advanced and metastatic NSCLC

Dr Marina Garassino Room 110

1:30pm - 3:00pm Oral abstract presentations: Basic science

Room 102

1:30pm - 3:30pm Oral abstract presentations: Data-driven quality

Room 103

1:30pm - 3:30pm Hope & Equity: Toward 2030 in lung cancer

Ms Lisa BriggsMr Tom WoodProf David Ball Prof Danielle MazzaA/Prof Rob StirlingA/Prof Angela Tod

Room 105/106

1:30pm - 3:30pm Symposium: Mesothelioma (proudly sponsored by Maurice Blackburn Lawyers)

Ms Dimitra Dubrow Prof Fraser Brims Dr Nicola Waddell Prof Ken O'Byrne A/Prof Gavin Wright Prof Anna Nowak A/Prof Gerry Hanna

Room 109

3:30pm - 4:30pm Abstract Awards followed by Closing Ceremony

Prof Kwun Fong A/Prof Tom John

Room 105/106

4:30pm - 4:45pm Afternoon tea

Thank you for joining us at ALCC 2020!

Friday program continued


Welcome from the ANZ-LCNF Chair

As Chair of the Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) I am very pleased to extend my warmest welcome to everyone attending the Australian Lung Cancer Conference 2020 in Melbourne.

The care provided by Lung Cancer Nurse Specialists improves clinical outcomes for patients with lung cancer. As 2020 is the International Year of the Nurse, I am particularly excited we are hosting the ANZ-LCNF workshop for nurses and allied health. This provides us with a great opportunity for networking and collaborating with clinicians, research experts, and many health professional members. It also gives us a unique occasion to shape how we can contribute to Lung Foundation Australia’s current key advocacy efforts as outlined in the strategic document ‘Making Lung Cancer A Fair Fight: A Blueprint for Reform’.

It is my great pleasure to welcome Professor Angela Mary Tod as the international nurse keynote speaker at this years’ workshop and conference.

I encourage all nurse an allied health attendees to enjoy all sessions provided in the ALCC 2020 program. Finally, I would like to echo the words of thanks extended by our conference convenors, Prof Kwun Fong and A/Prof Tom John to the sponsors and exhibitors.

Mary Duffy, APN, Lung Cancer Nurse Coordinator


ANZ-LCNF: Nursing and Allied Health Workshop ProgramWednesday 19 February

Session 1: Diagnostics and Quality of Care

Chair: Ms Mary Duffy, APN

Time Session Speaker

7:45am for 8:00am start

Registration

8:00am - 8:10am Welcome Ms Mary Duffy APN, ANZ-LCNF Chair

8:10am - 8:50am The impact of the specialist lung cancer nurse model on the health & wellbeing outcomes of patients and families

Prof Angela Tod

8:50am - 9:20am Lung cancer optimal care pathways Prof Robert Thomas

9:20am - 9:50am 2020: A year in review of lung cancer Dr Surein Arulananda

9:50am - 10:30am Roche sponsored session: Holistic care of the patient on Tecentriq and Avastin combination therapy

Ms Helen Westman Mr Michael Cooney

10:30am - 10:50am Morning tea

Session 2: Hope & Equity

Chair: Dr Vanessa Brunelli

10:50am - 11:15am The lived experience of lung cancer Mr Kane Morris

11:15am - 11:35am Telehealth to improve access and equity to cancer survivorship care

Dr Vanessa Brunelli

11:35am - 11:55am Equitable access to treatment in minority populations

Mrs Carolyn Riordan

11:55am - 12:15am Radiotherapeutic advances in the context of cerebral metastases

Dr Nikki Plumridge

12:15pm - 12:35pm Respiratory health and air quality Dr Alistair Miller

12:35pm - 1:05pm Lunch

This event is proudly sponsored by


Session 3: Living with Thoracic Cancer and Beyond

Chair: Dr Lara Edbrooke


1:10pm - 1:30pm Symptom management – challenges faced with new immune-oncology therapies

Ms Helen Westman

1:30pm - 1:50pm Cancer-related fatigue management Dr Elizabeth Pearson

1:50pm - 2:10pm Sarcopenia and cancer-related malnutrition Dr Nicole Kiss

2:10pm - 2:30pm Swallowing and voice outcomes after radiotherapy for SCLC

Dr Jacqui Frowen

2:30pm - 2:45pm Exercise across the lung cancer continuum Dr Lara Edbrooke

2:45pm - 3:05pm Afternoon tea

Session 4. Improving Nurse and Patient Outcomes in Lung Cancer

Chair: Dr Vanessa Brunelli


3:10pm - 3:30pm Smoking cessation in Australia: Practical strategies

Ms Kelly Burton

3:30pm - 3:50pm Clinical debrief and good self mental health Ms Tessa Moriarty

3:50pm - 4:10pm ANZ-LCNF research and education update Dr Vanessa Brunelli Ms Renae Grundy – PhD research

4:10pm Close Ms Mary Duffy APN, ANZ-LCNF Chair

4:20pm - 5:00pm Drinks and networking

ANZ-LCNF: program continued



IMFINZI® is a trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries: 1800 805 342 or [email protected]. To report an adverse event: 1800 805 342 or via https://aereporting.astrazeneca.com. AU-7238. WL303014. Date of preparation: January 2020.

CI: confidence interval; CRT: chemoradiation therapy; HR: hazard ratio; NSCLC: non-small cell lung cancer. References: 1. NCCN Guidelines. Non-small cell lung cancer v4.2019 (April 29 2019). Available at: www.nccn.org. 2. EviQ. Non small cell lung cancer durvalumab. ID: 3512 v.1. Available at: https://www.eviq.org.au. 3. Antonia SJ, et al. N Engl J Med 2018; 379:2342-50. 4. IMFINZI Approved Product Information. 5. McCall NS, et al. Clin Cancer Res 2018;24:1271-6. 6. Gray JE, et al. ASCO 2019. Poster 8526.

PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA.

PBS Information: This product is not listed on the PBS.

UNPRECEDENTED 3-YEAR OVERALL SURVIVAL BENEFIT

in patients with Stage III unresectable NSCLC whose disease has not progressed post platinum-based CRT (vs placebo;

HR 0.69, 95% CI, 0.55-0.86).4-6

THE STANDARD OF CARE FOR STAGE III UNRESECTABLE NSCLCthat has not progressed post platinum-based CRT1–5

Wednesday 19 February

Time Presentation Speaker

9:00am - 9:15am Welcome A/Prof Gerry HannaDr Louis Lao

9:15am - 10:15am Lung Cancer Radiotherapy: Where have we come from, where are we now and where are we going to?

Prof David Ball

10:15am - 10:45am Morning tea

10:45am - 11:30am Radiotherapy in small cell lung cancer Dr Eric Hau

11:30am - 12:00pm What is the optimal systemic therapy regimen to used in combination chemoradiation in NSCLC?

Dr Marina Garassino

12:00pm - 12:30pm AstraZeneca Sponsored Session: Considerations for CRT administration in stage III to limit post treatment complications?

Dr Marina Garassino Prof David Ball

12:30pm - 1:30pm Lunch

1:30pm - 1:45pm Motion management in NSCLC radiotherapy Dr Louise Nardone

1:45pm - 2:05pm Optimal dose and fractionation in the treatment of NSCLC with radiotherapy?

Dr Louis Lao

2:05pm - 2:20pm Proton therapy – Where did we get to? Dr Fiona Hegi-Johnson

2:20pm - 2:40pm Radiotherapy in thymoma and mesothelioma A/Prof Gerry Hanna

2:40pm - 3:10pm Afternoon Tea

3:10pm - 3:55pm Management of oligometastatic disease in NSCLC: Who, what, where, why and when?

A/Prof Shankar Siva

3:55pm - 4:00pm Session close A/Prof Gerry Hanna Dr Louis Lao

Co-Chairs: Dr Louis Lao and A/Prof Gerry Hanna

Faculty of Radiation Oncology Lung Interest Cooperative (FROLIC) Workshop ProgramWednesday 19 February

This event is proudly sponsored by


Australasian Lung Cancer Trials Group (ALTG)The Australasian Lung Cancer Trials Group (ALTG) is a member-based organisation representing respiratory physicians, medical oncologists, radiation oncologists, palliative care specialists, cardiothoracic surgeons, scientists, nurses, clinical trial professionals and consumer representatives.

Visit altg.com.au

ALTG objectives are:

• To facilitate participation in the development, conduct, evaluation, reporting of clinical trials in lung cancer and mesothelioma.

• To promote the use of clinical trials in evaluating new treatments and management approaches for lung cancer and mesothelioma.

• To contribute to the translation of clinical trial findings into clinical practice.

Benefits of ALTG membership include:

• A network of multidisciplinary professionals across Australia and New Zealand who are passionate about research for lung and thoracic cancers, such as clinicians, nursing, allied health, consumer and industry representatives.

• Support for developing your research ideas for investigator-initiated studies from concept to protocol and study conduct.

• Regular member meetings to develop research ideas and hear speakers on cutting-edge research topics.

• Educational opportunities including the ALTG Preceptorship in Lung Cancer and the ALTG Annual Scientific Meeting.

• Financial support to attend ALTG meetings in the form of travel grants.

Join ALTG today

Abstracts: Poster ListingDr Ayman Alidina - Immunotherapy in mesothelioma: Case studies from a regional cancer centre

Dr Prachi Bhave - Optimising pathways to maximal pathological diagnosis of metastatic non-small cell lung cancer

Dr Charlotte Chen - Surgical treatment of non-small cell lung cancer in octogenarians: A single centre retrospective study

Mrs Kirsten J Duggan - Lung cancer extent of disease, treatment patterns and survival - The effect of culturally and linguistically diverse status in south western Sydney

Dr James Farag - Surgical management of pulmonary artery angiomatoid fibrous histiosarcoma

Ms Tracey Guan - Lung cancer in patients aged 65+ years: Who do we treat and how do we treat them?

Dr Harshan Jeyakumar - Improving regional lung cancer optimal care pathway compliance through a rapid-access respiratory clinic

A/Prof Chee Lee - A phase 2 trial of Durvalumab (MEDI4736) and Tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer following progression on EGFR Tyrosine Kinase Inhibitors (ILLUMINATE)

Dr Jennifer Lim - Predictive biomarkers for platinum sensitivity in advanced non-small cell lung cancer – study schema

Prof Linda Mileshkin - A randomised phase 3 trial of early referral to palliative care for patients with advanced thoracic malignancies (PEARL)

Dr Cienne Morton - Survival outcomes and prognostic factors in unresectable Stage III NSCLC treated with concurrent chemoradiotherapy. A single institution audit from the Princess Alexandra Hospital, Brisbane

Dr Sara Pacella - Prognostic value of restaging 18F- FDG PET/CT in patients with small cell lung cancer

Ms Brielle Parris - Molecular testing of small bronchoscopy specimens using NanoString technology

Miss Sobasha Perera - Surveillance, patterns of recurrence and survivorship in early stage non-small cell lung cancer patients


For more information, visit us at Booth 10

© 2020 Bristol-Myers Squibb. OPDIVO® is a registered trademark of Bristol-Myers Squibb Company. BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3170. 1506AU2000940-01. Date of preparation: February 2020. BRMSCH1514.

In the era of molecular targeted therapies1

Unlock the potential of the only TKI approved for ROS1-positive NSCLC2-5

EGFR ALK ROS 1…testing

At diagnosis, request…

Recommended by ASCO, ESMO and NCCN6-9

References: 1. Nicholson AG et al. Sample Acquisition, Processing, and General Diagnostic Procedures. In Tsao MS, et al. IASLC Atlas Of ALK and ROS1 Testing in Lung Cancer. Second Edition. 2016. International Association for the Study of Lung Cancer, Aurora, CO, USA. 2. XALKORI Approved Product Information. 3. ALECENSA® (alectinib) Approved Product Information. 4. ZYKADIA® (ceritinib) Approved Product Information. 5. Shaw AT, et al. N Engl J Med. 2014; 371:1963-71. 6. National Comprehensive Cancer Network (NCCN). Non-small Cell Lung Cancer. Version 3. 2019 January 18, 2019. Available at www.nccn.org. Accessed February 2019. 7. Kalemkerian GP, et al. J Clin Oncol. 2018; 36 (9): 911-919. 8. Planchard D, et al. on behalf of the ESMO Guidelines Committee. Ann Oncol. 2018; 29 (Supplement_4): iv192-iv237. 9. Pavlakis, N et al . Pathology. 2019; 51(7):673-680

®Registered trademark. Pfizer Australia Pty Limited, Sydney, Australia.

Pfizer Medical Information: 1800 675 229.PFE1247. PP-XLK-AUS-0264. February 2020.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION IS AVAILABLE FROM THE TRADE DISPLAY.

PBS information: Authority required for the treatment of ALK+ & ROS1+ advanced NSCLC. Refer to the PBS Schedule for full authority information.

PFE1247_Xalkori_186x153.5mm_Ad_R3.indd 1PFE1247_Xalkori_186x153.5mm_Ad_R3.indd 1 12/2/20 3:43 pm12/2/20 3:43 pm

Miss Sophie Pickles - Investigating the role of mitochondria-targeted H2S donors for the treatment of NSCLC

Dr Kuan Pin Lim - Differences in lung cancer stage distribution in private and public hospital settings

Miss Aleksandra Rajapakse, Dr Connor O’Leary & Mr Ken O’Byrne - Autoimmune inner ear disease in an advanced lung cancer patient treated with nivolumab

Dr Nicole Rankin - Implementation of lung cancer multidisciplinary care: A rapid review of evidence-practice gaps

Ms Korinna Selga - Patient reported outcome measures in a Western Australian pilot group of lung cancer patients: Implementation of the continuous improvement in care - Cancer (CIC Cancer) Project

Dr Clare Senko - Cancer-testis antigens (CTAs), PD-L1 and overall survival in surgical non-small cell lung cancer: Potential immune mechanisms

Dr Prajwol Shrestha - A rare case of bullous pemphigoid associated with squamous cell carcinoma of lung showing remarkable response to carboplatin based chemotherapy in elderly: Case report and literature review

Dr Simon Slader - The concordance between clinical and pathological TNM stage in non-small cell lung cancer, a retrospective audit

Ms Catherine Smith - Demographics of patients with lung cancer diagnosed in the upper South Island of New Zealand: A ten-year audit

Dr Ashley Tan - Nobody expected the Spanish Inquisition! Lung cancers found in unexpected ways

Dr Ashley Tan - Early stage lung cancers detected in asymptomatic patients in an Australian private hospital setting

Dr Harshil Trivedi - Multidisciplinary team patterns of care for Stage III NSCLC and evaluation of guideline adherence – single-centre analysis

Dr Hannah Wade - Surgical rates in Stage I NSCLC: Audit of multidisciplinary team practice

Dr Veronica Wong & Dr Ashley Heyworth - FDG PET/CT for the staging of mediastinal lymph node involvement in lung cancer

Abstracts: Poster Listing continued


Abstracts Oral PresentationsDr Afaf Abed - Genomic HLA as a predictive marker for overall survival

in non-small cell lung cancer patients post immunotherapy

Dr Surein Arulananda - BCL-XL inhibition in combination with cisplatin

is effective in malignant pleural mesothelioma due to its dependency

on the BCL-XL pro-survival protein

Prof Fraser Brims - Targeted lung cancer screening in Australia: is there

a need to account for asbestos exposure?

Dr Kim-lin Chiew - A future role for quality indicators in lung cancer

multidisciplinary teams

Miss Vrushali Chimankar - Can genomic sequencing on mouse model

of lung cancer help us to understand the genetics of human lung

cancer?

Dr Venessa Chin - Single-cell transcriptomics and proteomics to assess

response to immunotherapy in real-time

Ms Vivienne Chipman - Building health literacy among culturally and

linguistically diverse Australians affected by lung cancer

Dr Laura Croft - A first in class DNA repair inhibitor for the treatment of

lung cancer

Dr Paul Dawkins - Development of national quality performance

indicators for lung cancer in New Zealand

Tracey Guan - QOOL-Dash: converting data to accessible information

for real-time monitoring of lung cancer outcomes for patients reviewed

at MDT in Queensland

Dr Pei Ding - Plasma ctDNA T790M mutation load predicts response

to second line Osimertinib in patients with advanced epidermal growth

factor receptor mutant non-small cell lung cancer: An Australian

multicentre retrospective study

Dr Lara Edbrooke - Physical activity levels are low in people with

inoperable lung cancer

Dr Samantha Ennis - Extent of emphysema in low dose CT scans

performed for lung cancer screening in an Australian cohort

Dr Fanny Franchini - Patterns of care in never-smokers versus smokers

in the treatment of lung cancer

Dr Marina Chiara Garassino - PD-L1 expression, patterns of progression

and patient-reported outcomes with Durvalumab plus Platinum-

Etoposide in extensive-stage small-cell lung cancer: Results from the

randomised, controlled, open label phase 3 CASPIAN trial

Dr Daryn Goodwin - The use of next generation sequencing in the

characterisation of multiple primary lung cancers

Dr Daniel Gough - STAT3 deletion increases metastatic small cell lung

cancer

Dr Susan Harden - Utilising a national clinical quality registry to drive

improvement in lung cancer outcomes: Radiation oncology examples

from the UK National Lung Cancer Audit

Prof Rina Hui - KEYNOTE-024 3-year survival update: Pembrolizumab

vs Platinum-Based Chemotherapy for advanced non-small cell lung

cancer

Ms Elena Jensen-Marini - Exploring patient reported quality of life in

lung cancer patients: A qualitative study

A/Prof Tom John - Osimertinib vs comparator EGFR-TKI as first-line

treatment for EGFRm advanced non-small cell lung cancer (FLAURA):

Final overall survival analysis

Dr Kuan Pin Lim - Comparing recruitment strategies in lung cancer

screening: GP-based mail-outs or population-based mail-outs?

Dr Patrick MaClean - Influence of the time interval from diagnosis to

treatment on survival for early-stage non-small cell lung cancer

Prof Michael Macmanus - What proportion of patients commence

but fail to complete curative-intent chemoradiotherapy for non-small

cell lung cancer?

Dr Lin Mo - The international lung screen trial: Results from three

Australian sites

Ms Kirsten Mooney - Harnessing innovation to improve outcomes

for lung cancer patients: Proof of concept for prehabilitation within a

tertiary hospital.

Mr Preston Ngo - Real-world treatment patterns for lung cancer:

Systemic therapy utilisation and factors relating to treatment in

Australia

Prof Nir Peled - Pembrolizumab plus Chemotherapy for advanced

NSCLC without tumor PD-L1 expression: Pooled analysis of KEYNOTE-

021G, KEYNOTE-189 and KEYNOTE-407

Dr Jonathan Pham - Excess mortality in elderly patients diagnosed

with advanced lung cancer is related to under-prescribing of active

treatments, after controlling for confounders

Dr Hema Ramarmuty - Convex probe EBUS bronchoscopy guided

placement of fiducial marker in oligo-metastatic mediastinal lymph

nodes for cyberKnife stereotactic body radiotherapy – Safety and

feasibility

Dr Nicole Rankin - The potential for implementation of LDCT lung

cancer screening in the Australian setting: outcomes of an evidence

check review

Miss Katherine Bahar Sahin - Evaluation of AURKA inhibition as a

novel strategy to improve EGFR-mutant tumour response to tyrosine

kinase inhibitors

Miss Priyanka Sahu - Novel mouse model for investigating the

pathogenesis of early stage squamous cell lung carcinoma

A/Prof Jasotha Sanmugarajah - 30-day mortality following

intravenous systemic therapy for non-small cell lung cancer patients

in Queensland

Dr Matthew Soeberg - Lung cancer and its association with asbestosis

mortality: What can we find out from Australia’s cause of death data

Dr Emily Stone - ILST Australia: Impact of recruitment strategy

on eligibility rates for LDCT lung cancer screening at baseline in an

Australian centre

Dr Emily Stone - ILST (International Lung Screen Trial) Australia:

Baseline results at an Australian trial centre for low dose CT screening

for lung cancer

Dr Amila Suraweera - Defining a novel DNA repair protein as an anti-

cancer therapeutic target in non-small cell lung cancer

Dr Kate Sutherland - Harnessing natural killer immunity in metastatic

small cell lung cancer

Ms Louise Underhill - “Hanging on the telephone” – measuring the

impact of a telephone-based specialist lung cancer nursing service

Dr Stephen Wade - Estimated smoking rates over the next 50 years

in Australia

Dr Marianne Weber - Estimated risk for lung cancer incidence and

mortality related to tobacco smoking among 229,028 Australians

Tracey Guan - Lung cancer clinical practice indicators for Queensland:

A work in progress

A/Prof Jasotha Sanmugarajah - Timely lung cancer care is influenced

by stage at diagnosis, a population-wide study from Queensland

Mrs Hui You - Patterns of treatment and survival for people with small

cell lung cancer in NSW

Standard OralRapid FireNew Investigator


How can you support us?

Invest in the Future

Scientific breakthroughs can take years to accomplish. Invest in a future free from lung disease by leaving a bequest or gift as part of your Will. Leaving a bequest is a way of ensuring you can continue to support the causes that are special to you, even after you’re gone. Equally, talking with your family about a Gift in Memoriam celebrates your life and gives hope to others.

Help Find a Cure

Your donation can help us understand the causes and future treatments of lung disease. Regular giving is our most precious source of revenue. It gives us certainty and continuity in an unpredictable funding environment and provides an independent source of funding. A donation of $5.00 per week goes a long way. Put simply regular donations allow great science to flourish.

Get Involved

More than ever, Australians are aware of the need to increase research funding to fight lung disease and give hope to their fellow Australians. Share your story, become a Lung Foundation Australia Ambassador or join workplace giving. There are many ways you can support Lung Foundation Australia and make a difference.

Philanthropy and Partnerships

Lung Foundation Australia is proud to partner with philanthropists, companies, trusts and foundations to raise vital funds for lung disease research. We focus on forming personalised connections with donors and supporters to achieve our mission. We are outcomes focused and ensure your investment is tracked against measurable goals. As with all our support, we keep you up-to-date on progress. This is our promise.

Community Fundraising

Celebrate hope and support your loved one, friend or work colleague by doing something you love. Join our team, take part in a fun run, cycle or hold an event.

Date post:	15-Jan-2022
Category:	Documents
Upload:	others
View:	5 times
Download:	0 times

8th Australian Lung Cancer Conference 2020

Documents